KR960702442A - 타이로신 키나아제 억제인자로서의 치환된 β-아릴 및 β-헤테로아릴-α-시아노아크릴아미드 유도체(Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors) - Google Patents
타이로신 키나아제 억제인자로서의 치환된 β-아릴 및 β-헤테로아릴-α-시아노아크릴아미드 유도체(Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors)Info
- Publication number
- KR960702442A KR960702442A KR1019950705290A KR19950705290A KR960702442A KR 960702442 A KR960702442 A KR 960702442A KR 1019950705290 A KR1019950705290 A KR 1019950705290A KR 19950705290 A KR19950705290 A KR 19950705290A KR 960702442 A KR960702442 A KR 960702442A
- Authority
- KR
- South Korea
- Prior art keywords
- cyanoacrylamide
- hydroxy
- indolyl
- tetrahydronaphth
- compound
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D401/00—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom
- C07D401/02—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings
- C07D401/12—Heterocyclic compounds containing two or more hetero rings, having nitrogen atoms as the only ring hetero atoms, at least one ring being a six-membered ring with only one nitrogen atom containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C255/00—Carboxylic acid nitriles
- C07C255/01—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms
- C07C255/32—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring
- C07C255/41—Carboxylic acid nitriles having cyano groups bound to acyclic carbon atoms having cyano groups bound to acyclic carbon atoms of a carbon skeleton containing at least one six-membered aromatic ring the carbon skeleton being further substituted by carboxyl groups, other than cyano groups
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/12—Radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D209/00—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
- C07D209/02—Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
- C07D209/04—Indoles; Hydrogenated indoles
- C07D209/10—Indoles; Hydrogenated indoles with substituted hydrocarbon radicals attached to carbon atoms of the hetero ring
- C07D209/18—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/12—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with substituted hydrocarbon radicals attached to ring carbon atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D215/00—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems
- C07D215/02—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom
- C07D215/16—Heterocyclic compounds containing quinoline or hydrogenated quinoline ring systems having no bond between the ring nitrogen atom and a non-ring member or having only hydrogen atoms or carbon atoms directly attached to the ring nitrogen atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
- C07D215/20—Oxygen atoms
- C07D215/24—Oxygen atoms attached in position 8
- C07D215/26—Alcohols; Ethers thereof
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D217/00—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems
- C07D217/12—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring
- C07D217/14—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals
- C07D217/16—Heterocyclic compounds containing isoquinoline or hydrogenated isoquinoline ring systems with radicals, substituted by hetero atoms, attached to carbon atoms of the nitrogen-containing ring other than aralkyl radicals substituted by oxygen atoms
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/04—One of the condensed rings being a six-membered aromatic ring
- C07C2602/10—One of the condensed rings being a six-membered aromatic ring the other ring being six-membered, e.g. tetraline
Abstract
본 발명은 신규한 일반식(Ⅰ)의 화합물 및 이의 약제학적으로 허용되는 염에 관한 것이다.
상기식에서, A는 나프탈렌, 테트라하이드로나프탈렌, 퀴놀린, 이소퀴놀린 및 인돌로부터 선택된 비사이클릭 환이고; B는 R2치환된 벤젠 환 또는 치환되지 않은 피리딘 또는 티오펜 환이고; R은 수소, C1내지 C6알킬, 할로겐, 니트로, 시아노, 카복시 또는 그룹 NR3R4여기서, R3및 R4는 각각 독립적으로 수소 또는 C1내지 C6알킬이다)이고; R1은 수소, C1내지 C6알킬 또는 C1내지 C6알카노일이고; R2는 수소, C1내지 C6알킬, 할로겐, 니트로, 시아노, 카복시, 하이드록시, C1내지 C6알콕시, C1내지 C6알카노일옥시 또는 그룹 NR3R4(여기서, R3및 R4는 상기 정의한 바와 같다)이고; n은 0, 또는 1 또는 2의 정수이고; x는 0 또는 1 내지 5의 정수중 하나이다.
본 발명의 화합물은 타이로신 키나아제 억제인자로서 유용하다.
Description
본 내용은 요부공개 건이므로 전문내용을 수록하지 않았음
Claims (14)
- 일반식(Ⅰ)의 화합물 및 이의 약제학적으로 허용되는 염.상기식에서, A는 나프탈렌, 테트라하이드로나프탈렌, 퀴놀린, 이소퀴놀린및 인돌로부터 선택된 비사이클릭 환이고; B는 R2치환된 벤젠 환 또는 치환되지 않은 피리딘 또는 티오펜 환이고; R은 수소, C1내지 C6알킬, 할로겐, 니트로, 시아노, 카복시 또는 그룹 NR3R4(여기서, R3및 R4는 각각 독립적으로 수소 또는 C1내지 C6알킬이다)이고; R1은 수소, C1내지 C6알킬 또는 C1내지 C6알카노일이고; R2는 수소, C1내지 C6알킬, 할로겐, 니트로, 시아노, 카복시, 하이드록시, C1내지 C6알콕시, C1내지 C6알카노일옥시 또는 그룹 NR3R4여기서, R3및 R4는 상기 정의한 바와 같다)이고; n은 O, 또는 1 또는 2의 정수이고; x는 O 또는1 내지 5의 정수 중 하나이다.
- 제1항에 있어서, A가 테트라하이드로나프탈렌, 퀴놀린, 이소퀴놀린 또는 인돌이고; B가 R2치환된 벤젠 또는 치환되지 않은 피리딘이고; R은, R이 또한 카복시 또는 아미노일 수 있는 인돌 유도체를 제외하고는, 수소 또는 할로겐이고; R1이 수소 또는 메틸이고; R2가 수소, 할로겐, 시아노, 하이드록시, 카복시 또는 아미노이고; n이 0,1 또는 2이고; x가 0,1,2 또는 3인 일반식(Ⅰ)의 화합물 및 이의 약제학적으로 허용되는 염.
- 제2항예 있어서, A가 테트라하이드로나프탈렌, 퀴놀린, 이소퀴놀린 또는 인돌이고; B가 R2치환된 벤젠 또는 치환되지 않은 피리딘이고; R은, R이 또한 카복시 또는 아미노일 수 있는 인돌 유도체를 제외하고는 수소이고; R1이 수소 또는 메틸이고; R2가 수소 또는 하이드록시이고; n이 0 또는 1이고; x가 0,1 또는 2인일반식(Ⅰ)의 화합물 및 이의 약제학적으로 허용되는 염.
- (Z)-이성질체 또는 (E)-이성질체, 또는 (Z)-이성질체와 (E)-이성질체의 혼합물 형태인, 하기 화합물로 이루어지는 그룹으로부터 선택되는 화합물, 또는 이의 약제학적으로 허용되는 염.N-페닐β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-(4'-하이드록시페닐)-β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-페닐β-(3,4-디하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-(4'-하이드록시페닐)β-(3,4-디하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-벤질β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-(4'-하이드록시벤질)β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-벤질β-(3,4-디하이드록시-5,6,7.8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-(4'-하이드록시벤질)β-(3,4-디하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-펜에틸β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-(4'-하이드록시펜에틸)β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-펜에틸β-(3,4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-(4'-하이드록시펜에틸)β-(3,4-디하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-페닐β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)-α-시아노아크릴아미드; N-(4'-하이드록시페닐)-β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)-α-시아노아크릴아미드; N-벤질β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)-α-시아노아크릴아미드; N-(4'-하이드록시벤질)β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)-α-시아노아크릴아미드; N-펜에틸β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)-α-시아노아크릴아미드; N-(4'-하이드록시펜에틸)β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-2-일)-α-시아노아크릴아미드; N-페닐β-(4-퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시페닐)β-(4-퀴놀릴)-α-시아노아크릴아미드; N-벤질 β-(4-퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시벤질)β-(4-퀴놀릴)-α-시아노아크릴아미드; N-펜에틸β-(4-퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시펜에틸)β-(4-퀴놀릴)-α-시아노아크릴아미드; N-페닐β-(8-하이드록시-5-퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시페닐)β-(8-하이드록시-5-퀴놀릴)-α-시아노아크릴아미드; N-벤질β-(8-하이드록시-5-퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시벤질)β-(8-하이드록시-5-퀴놀릴)-α-시아노아크릴아미드; N-펜에틸β-(8-하이드록시-5-퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시펜에틸)β-(8-하이드록시-5-퀴놀릴)-α-시아노아크릴아미드; N-페닐β-(3-이소퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시페닐)β-(3-이소퀴놀릴)-α-시아노아크릴아미드; N-벤질β-(3-이소퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시벤질)β-(3-이소퀴놀릴)-α-시아노아크릴아미드; N-펜에틸β-(3-이소퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시펜에틸)β-(3-이소퀴놀릴)-α-시아노아크릴아미드; N-페닐β-(5-이소퀴놀릴)-α-시아노아크릴아미드; N-(4-하이드록시페닐)β-(5-이소퀴놀릴)-α-시아노아크릴아미드; N-벤질β-(5-이소퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시벤질)β-(5-이소퀴놀릴)-α-시아노아크릴아미드; N-펜에틸 β-(5-이소퀴놀릴)-α-시아노아크릴아미드; N-(4'-하이드록시펜에틸)β-(5-이소퀴놀릴)-α-시아노아크릴아미드; N-페닐β-(3-인돌릴)-α-시아노아크릴아미드; N-벤질β-(3-인돌릴)-α-시아노아크릴아미드; N-펜에틸β-(3-인돌릴)-α-시아노아크릴아미드; N-페닐β-(5-하이드록시-3-인돌릴)-α-시아노아크릴아미드; N-벤질β-(5-하이드록시-3-인돌릴)-α-시아노아크릴아미드; N-펜에틸β-(5-하이드록시-3-인들릴)-α-시아노아크릴아미드; N-페닐β-(5-카복시-3-인돌릴)-α-시아노아크릴아미드; N-벤질β-(5-카복시-3-인돌릴)-α-시아노아크릴아미드; N-펜에틸β-(5-카복시-3-인돌릴)-α-시아노아크릴아미드; N-페닐β-(5-아미노-3-인돌릴)-α-시아노아크릴아미드; N-벤질β-(5-아미노-3-인돌릴)-α-시아노아크릴아미드; N-펜에틸β-(5-아미노-3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시페닐)β-(3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시벤질)β-(3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시펜에틸)β-(3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시페닐)β-(5-하이드록시-3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시벤질) β-(5-하이드록시-3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시펜에틸)β-(5-하이드록시-3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시페닐)β-(5-카복시-3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시벤질)β-(5-카복시-3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시펜에틸)β-(5-카복시-3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시페닐)β-(5-아미노-3-인돌릴)-α-시아노아크릴아미드; N-(4'-하이드록시벤질)β-(5-아미노-3-인돌릴)-α-시아노아크릴아미드; N-페닐β-(5-메톡시-3-인돌릴)-α-시아노아크릴아미드; N-벤질β-(5-메톡시-3-인돌릴)-α-시아노아크릴아미드; N-(3-피리딜)β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-(3-피리딜)β-(3-인돌릴)-α-시아노아크릴아미드; N-(3-피리딜)β-(5-메톡시-3-인돌릴)-α-시아노아크릴아미드; N-(3-피리딜)β-(4-퀴놀릴)-α-시아노아크릴아미드; N-(3-피리딜메틸)β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아미드; N-(3-피리딜메틸)β-(3-인돌릴)-α-시아노아크릴아미드; N-(3-피리딜메틸)β-(5-메톡시-3-인돌릴)-α-시아노아크릴아미드; N-(3-피리딜메틸)β-(4-퀴놀릴)-α-시아노아크릴아미드; N-(2-피리딜메틸)β-(4-하이드록시-5,6,7,8-테트라하이드로나프트-1-일)-α-시아노아크릴아이드; N-(2-피리딜메틸)β-(3-인돌릴)-α-시아노아크릴아미드; N-(2-피리딜메틸)β-(5-메톡시-3-인돌릴)-α-시아노아크릴아미드; N-(2-피리딜메틸)β-(4-퀴놀릴)-α-시아노아크릴아미드.
- 일반식(Ⅱ)의 알데히드와 일반식(Ⅲ)의 화합물을 축합시키고, 경우에 따라, 일반식(Ⅰ)의 화합물을 또다른 일반식(Ⅰ)의 화합물로 전환시키고/시키거나, 경우에 따라, 일반식(Ⅰ)의 화합물을 이의 약제학적으로 허용되는 염으로 전환시키고/시키거나, 경우에 따라, 염을 유리 화합물로 전환시키고/시키거나, 경우에 따라, 일반식(Ⅰ)의 화합물의 이성질체의 혼합물을 단일 이성질체로 분리시킴을 포함하는, 제1항에 따른 일반식(Ⅰ)의 화합물의 제조방법.NC-CH2CONH-(CH2)x-B (Ⅲ)상기식에서, A, R, R1, R2, n 및 x는 제1항에서 정의된 바와 같다.
- 적합한 담체 및/또는 희석제, 및 활성성분으로서의 제1항에 따른 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염을 포함하는 약제학적 조성물.
- 제1항에 있어서, 타이로신 키나아제 억제인자로서 사용하기 위한 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.
- 제7항에 있어서, 항암제로서 또는 백혈병, 건선 또는 아테롬성 플라크의 치료에 사용하기 위한 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.
- 제7항에 있어서, 면역억제제로서 사용하기 위한 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.
- 타이로신 키나아제 억제인자로서 사용하기 위한 약제의 제조에 있어서의, 제1항에 따른 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염의 용도.
- 항암제로서 또는 백혈병, 건선 또는 아테롬성 플라크의 치료에 사용하기 위한 약제의 제조에 있어서의, 제9항에 따른 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염의 용도.
- 면역억제제로서 사용하기 위한 약제의 제조에 있어서의, 제9항에 따른 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염의 용도.
- 제1항에 있어서, 인체 또는 동물체의 치료방법에서 치료법으로 사용하기 위한 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염.
- 항암 치료법에서 동시에, 별개로 또는 순차적으로 사용하기 위한 조합 제제로서, 제1항에 따른 일반식(Ⅰ)의 화합물 또는 이의 약제학적으로 허용되는 염과 항종양제를 함유하는 생성물.※ 참고사항 : 최초출원 내용에 의하여 공개하는 것임.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
GB9406137.1 | 1994-03-28 | ||
GB9406137A GB9406137D0 (en) | 1994-03-28 | 1994-03-28 | N-substituted beta-aryl- and betaheteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation |
PCT/EP1995/000758 WO1995026341A1 (en) | 1994-03-28 | 1995-03-02 | Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors |
Publications (1)
Publication Number | Publication Date |
---|---|
KR960702442A true KR960702442A (ko) | 1996-04-27 |
Family
ID=10752648
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1019950705290A KR960702442A (ko) | 1994-03-28 | 1995-03-02 | 타이로신 키나아제 억제인자로서의 치환된 β-아릴 및 β-헤테로아릴-α-시아노아크릴아미드 유도체(Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors) |
Country Status (21)
Country | Link |
---|---|
US (1) | US5652250A (ko) |
EP (1) | EP0700388B1 (ko) |
JP (1) | JPH08511562A (ko) |
KR (1) | KR960702442A (ko) |
CN (1) | CN1125942A (ko) |
AT (1) | ATE224371T1 (ko) |
AU (1) | AU685599B2 (ko) |
DE (1) | DE69528229T2 (ko) |
ES (1) | ES2183866T3 (ko) |
FI (1) | FI955661A (ko) |
GB (1) | GB9406137D0 (ko) |
HU (1) | HUT73811A (ko) |
IL (1) | IL113044A0 (ko) |
MX (1) | MX9504895A (ko) |
MY (1) | MY130160A (ko) |
NO (1) | NO954692L (ko) |
NZ (1) | NZ281630A (ko) |
PL (1) | PL311745A1 (ko) |
TW (1) | TW347386B (ko) |
WO (1) | WO1995026341A1 (ko) |
ZA (1) | ZA952423B (ko) |
Families Citing this family (17)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9613021D0 (en) * | 1996-06-21 | 1996-08-28 | Pharmacia Spa | Bicyclic 4-aralkylaminopyrimidine derivatives as tyrosine kinase inhibitors |
WO1997049653A2 (en) * | 1996-06-24 | 1997-12-31 | Irori | Solid phase tyrphostin library linked to matrices with memories |
EP1060160A2 (en) | 1998-02-27 | 2000-12-20 | THE UNITED STATES GOVERNMENT as represented by THE DEPARTMENT OF HEALTH AND HUMAN SERVICES | Disubstituted lavendustin a analogs and pharmaceutical compositions comprising the analogs |
HUP0000920A3 (en) * | 2000-02-28 | 2002-03-28 | Sanofi Synthelabo | Pde4 inhibitor isoquinolinylidene derivatives, process for their preparation and medicaments containing them |
EP1752446A3 (en) * | 2000-04-13 | 2007-03-21 | HSC Research and Development Limited Partnership | Compounds for modulating cell proliferation |
JP2003531133A (ja) | 2000-04-13 | 2003-10-21 | エイチエスシー リサーチ アンド ディベロップメント リミテッド パートナーシップ | 細胞増殖を調節する新規化合物 |
US20050014690A1 (en) * | 2001-10-11 | 2005-01-20 | Chaim Roifman | Styryl acrylonitrile compounds and their use to promote myelopoiesis |
JP4751336B2 (ja) * | 2003-12-11 | 2011-08-17 | ボード・オブ・リージエンツ,ザ・ユニバーシテイ・オブ・テキサス・システム | 細胞増殖性疾患を治療する化合 |
US7598419B2 (en) | 2004-03-26 | 2009-10-06 | Hsc Research And Development Limited Partnership | Compounds for modulating cell proliferation |
US20100292229A1 (en) * | 2006-06-30 | 2010-11-18 | The Board Of Regents Of The University Of Texas System | Tryphostin-analogs for the treatment of cell proliferative diseases |
EP2307367B1 (en) | 2008-07-08 | 2014-09-24 | Board of Regents, The University of Texas System | Novel inhibitors of proliferation and activation of signal transducer and activator of transcription (stats) |
EP2558099A4 (en) * | 2009-11-16 | 2013-07-17 | Univ California San Francisco | Kinase Inhibitors |
CN103459371A (zh) * | 2011-04-02 | 2013-12-18 | 中国人民解放军军事医学科学院毒物药物研究所 | 芳基丙烯酰胺化合物及其用于制备免疫抑制剂的用途 |
HUE048834T2 (hu) * | 2011-05-17 | 2020-08-28 | Univ California | Kináz inhibitorok |
US10214476B2 (en) * | 2011-12-30 | 2019-02-26 | Ecole Nationale Superieure De Chimie De Clermont Ferrand | Pain relief compounds |
JP2016537316A (ja) * | 2013-10-10 | 2016-12-01 | ザ リージェンツ オブ ザ ユニバーシティー オブ ミシガン | デユビキチナーゼ阻害剤およびその使用方法 |
CN108276366B (zh) * | 2018-01-08 | 2021-09-03 | 四川大学 | 一种丙烯酰胺类衍生物及其制备方法与应用 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
GB9000939D0 (en) * | 1990-01-16 | 1990-03-14 | Erba Carlo Spa | Improvement in the total synthesis of erbstatin analogs |
GB9000950D0 (en) * | 1990-01-16 | 1990-03-14 | Erba Carlo Spa | New arylvinylamide derivatives and process for their preparation |
GB9004483D0 (en) * | 1990-02-28 | 1990-04-25 | Erba Carlo Spa | New aryl-and heteroarylethenylene derivatives and process for their preparation |
US5196446A (en) * | 1990-04-16 | 1993-03-23 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Certain indole compounds which inhibit EGF receptor tyrosine kinase |
AU662480B2 (en) * | 1990-04-16 | 1995-09-07 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Heterocyclicethenediyl compounds which inhibit EGF receptor tyrosine kinase |
GB9115160D0 (en) * | 1991-07-12 | 1991-08-28 | Erba Carlo Spa | Methylen-oxindole derivatives and process for their preparation |
CA2080554A1 (en) * | 1991-10-15 | 1993-04-16 | Mitsubishi Chemical Corporation | Styrene derivatives |
GB9204945D0 (en) * | 1992-03-06 | 1992-04-22 | Erba Carlo Spa | 3-aryl-glycidic ester derivatives and process for their preparation |
GB9226855D0 (en) * | 1992-12-23 | 1993-02-17 | Erba Carlo Spa | Vinylene-azaindole derivatives and process for their preparation |
-
1994
- 1994-03-28 GB GB9406137A patent/GB9406137D0/en active Pending
-
1995
- 1995-03-02 DE DE69528229T patent/DE69528229T2/de not_active Expired - Fee Related
- 1995-03-02 WO PCT/EP1995/000758 patent/WO1995026341A1/en active IP Right Grant
- 1995-03-02 US US08/537,947 patent/US5652250A/en not_active Expired - Fee Related
- 1995-03-02 JP JP7524920A patent/JPH08511562A/ja not_active Ceased
- 1995-03-02 EP EP95910542A patent/EP0700388B1/en not_active Expired - Lifetime
- 1995-03-02 AU AU18498/95A patent/AU685599B2/en not_active Expired - Fee Related
- 1995-03-02 NZ NZ281630A patent/NZ281630A/en unknown
- 1995-03-02 HU HU9503714A patent/HUT73811A/hu unknown
- 1995-03-02 MX MX9504895A patent/MX9504895A/es unknown
- 1995-03-02 CN CN95190227A patent/CN1125942A/zh active Pending
- 1995-03-02 KR KR1019950705290A patent/KR960702442A/ko not_active Application Discontinuation
- 1995-03-02 AT AT95910542T patent/ATE224371T1/de not_active IP Right Cessation
- 1995-03-02 PL PL95311745A patent/PL311745A1/xx unknown
- 1995-03-02 ES ES95910542T patent/ES2183866T3/es not_active Expired - Lifetime
- 1995-03-15 MY MYPI95000645A patent/MY130160A/en unknown
- 1995-03-20 IL IL11304495A patent/IL113044A0/xx unknown
- 1995-03-23 TW TW084102825A patent/TW347386B/zh active
- 1995-03-24 ZA ZA952423A patent/ZA952423B/xx unknown
- 1995-11-20 NO NO954692A patent/NO954692L/no unknown
- 1995-11-24 FI FI955661A patent/FI955661A/fi not_active Application Discontinuation
Also Published As
Publication number | Publication date |
---|---|
AU685599B2 (en) | 1998-01-22 |
ATE224371T1 (de) | 2002-10-15 |
ZA952423B (en) | 1995-12-19 |
TW347386B (en) | 1998-12-11 |
IL113044A0 (en) | 1995-06-29 |
HUT73811A (en) | 1996-09-30 |
NZ281630A (en) | 1998-02-26 |
EP0700388A1 (en) | 1996-03-13 |
JPH08511562A (ja) | 1996-12-03 |
MY130160A (en) | 2007-06-29 |
NO954692D0 (no) | 1995-11-20 |
DE69528229T2 (de) | 2003-08-14 |
HU9503714D0 (en) | 1996-02-28 |
CN1125942A (zh) | 1996-07-03 |
MX9504895A (es) | 1998-03-31 |
PL311745A1 (en) | 1996-03-18 |
US5652250A (en) | 1997-07-29 |
EP0700388B1 (en) | 2002-09-18 |
ES2183866T3 (es) | 2003-04-01 |
WO1995026341A1 (en) | 1995-10-05 |
AU1849895A (en) | 1995-10-17 |
FI955661A0 (fi) | 1995-11-24 |
FI955661A (fi) | 1996-01-19 |
DE69528229D1 (en) | 2002-10-24 |
GB9406137D0 (en) | 1994-05-18 |
NO954692L (no) | 1995-11-20 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
KR960702442A (ko) | 타이로신 키나아제 억제인자로서의 치환된 β-아릴 및 β-헤테로아릴-α-시아노아크릴아미드 유도체(Substituted beta-aryl and beta-heteroaryl-alpha-cyanoacrylamide derivatives as tyrosine kinase inhibitors) | |
KR960700707A (ko) | 맥관형성 억제제로서 유용한, 생물학적 활성의 3-치환된 옥신돌 유도체(Biologically active 3-substituted oxindole derivatives useful as anti-angiogenic agents) | |
KR950702979A (ko) | 티로신 키나제 억제제로서의 아릴리덴 및 헤테로아릴리덴 옥신돌 유도체(Arylidene and heteroarylidene oxindole derivatives as tyrosine kinase inhibitors) | |
GB9004483D0 (en) | New aryl-and heteroarylethenylene derivatives and process for their preparation | |
US3944675A (en) | Substituted aryl and aralkyl amides in the treatment of parkinsonism | |
GB1469197A (en) | Preparation of 1-aminoalkyl triazolobenzodiazepines | |
AU635908B2 (en) | 2-aminocarboxylic acid derivatives, their manufacture and use as drugs | |
US5948781A (en) | Adamantyl substituted oxindoles as pharmaceutical agents | |
RU95122385A (ru) | N-ЗАМЕЩЕННЫЕ ПРОИЗВОДНЫЕ β -АРИЛ- И β -ГЕТЕРО-АРИЛ- α -ЦИАНАКРИЛАМИДОВ, СПОСОБ ИХ ПОЛУЧЕНИЯ, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ | |
RU94046310A (ru) | Эфиры никотиновой кислоты, способ их получения, способ получения промежуточных соединений, фармацевтическая композиция и способ лечения | |
KR930017874A (ko) | 포화 질소 헤테로사이클의 유도체 | |
GB1589752A (en) | 5,6-dihydro-3-phenyl-imidazo(5,1-a)isoquinolines | |
EP0810223B1 (en) | Adamantyl substituted oxindoles as pharmaceutical agents | |
IL79280A (en) | 4-(6-oxo-dihydro or tetrahydropyridazin-3-yl)benzene derivatives,their preparation and pharmaceutical compositions containing them | |
GB2262524A (en) | Pharmaceutically active 2-hydroxy-benzylamines | |
CA2163115A1 (en) | N-substituted beta-aryl- and beta-heteroaryl-alpha-cyanoacrylamide derivatives and process for their preparation | |
HUT34943A (en) | Process for the production of new 1,1-diphenyl-propanol-derivatives, as well as of therapeutic preparations containing them | |
KR890014535A (ko) | 인돌화합물 및 이들의 제조방법, 및 이들 화합물을 함유하는 약학적 조성물 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
WITN | Application deemed withdrawn, e.g. because no request for examination was filed or no examination fee was paid |